BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer

Concurrent/adjuvant cisplatin-based chemoradiotherapy is regarded as the standard of treatment for locoregionally advanced nasopharyngeal carcinoma (NPC). However, patients who do not respond to cisplatin suffer, rather than benefit, from chemotherapy treatment. The goal of this study was to identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuang, Chun-mei, Fu, Xiang, Hua, Yi-jun, Shuai, Wen-di, Ye, Zhi-hua, Li, Yingchang, Peng, Qi-hua, Li, Yi-zhuo, Chen, Shuai, Qian, Chao-nan, Huang, Wenlin, Liu, Ran-yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520926/
https://www.ncbi.nlm.nih.gov/pubmed/28617432
http://dx.doi.org/10.1038/cddis.2017.271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520926/
https://www.ncbi.nlm.nih.gov/pubmed/28617432
http://dx.doi.org/10.1038/cddis.2017.271

Ejemplares similares